Northern Trust Corp boosted its holdings in shares of BioTime, Inc. (NYSEAMERICAN:BTX) by 5.2% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 1,016,226 shares of the biotechnology company’s stock after buying an additional 49,778 shares during the quarter. Northern Trust Corp’s holdings in BioTime were worth $2,094,000 as of its most recent SEC filing.
Separately, Bank of New York Mellon Corp increased its position in BioTime by 4.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 744,554 shares of the biotechnology company’s stock valued at $1,534,000 after buying an additional 33,350 shares in the last quarter.
BioTime stock opened at $1.43 on Friday. BioTime, Inc. has a fifty-two week low of $1.39 and a fifty-two week high of $3.16.
BioTime (NYSEAMERICAN:BTX) last posted its quarterly earnings results on Thursday, November 8th. The biotechnology company reported ($0.07) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by ($0.01). The business had revenue of $0.98 million during the quarter, compared to analyst estimates of $0.75 million.
Separately, Zacks Investment Research lowered BioTime from a “buy” rating to a “hold” rating in a research report on Wednesday, October 3rd.
ILLEGAL ACTIVITY NOTICE: “BioTime, Inc. (BTX) Position Lifted by Northern Trust Corp” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/12/01/biotime-inc-btx-position-lifted-by-northern-trust-corp.html.
BioTime, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies primarily in the United States and Israel. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; and Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy.
Recommended Story: Fundamental Analysis
Want to see what other hedge funds are holding BTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioTime, Inc. (NYSEAMERICAN:BTX).
Receive News & Ratings for BioTime Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime and related companies with MarketBeat.com's FREE daily email newsletter.